|Table of Contents|

Value of 18F-FDG PET/CT in predicting EGFR mutations in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 05
Page:
787-790
Research Field:
Publishing date:

Info

Title:
Value of 18F-FDG PET/CT in predicting EGFR mutations in non-small cell lung cancer
Author(s):
Zeng Fanshun1; Yu Lijuan1; 2; Ma Jingquan1; Wang Xin1; Liang Bangyu1
1.Department of Cancer Hospital，Harbin Medical University，Heilongjiang Harbin 150081，China；2.Hainan Cancer Hospital，Hainan Haikou 570100，China.
Keywords:
non-small cell lung cancer; 18F-fluorodeoxyglucose positron emission tomography-computed tomography; epidermal growth factor receptor
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.05.018
Abstract:
Objective：To investigate the value of maximum standardized uptake value(SUVmax)，metabolic tumor volume(MTV) measured by 18F-fluorodeoxyglucose positron emission tomography(18F-FDG PET/CT) in predicting the presence of epidermal growth factor receptor(EGFR) mutation status in non-small cell lung cancer(NSCLC).Methods： We retrospectively reviewed 141 patients with NSCLC confirmed by pathology，who underwent 18F-FDG PET/CT examination and EGFR mutation analysis before any treatment.To analyze the correlation between clinical pathological data and PET/CT metabolic parameters SUVmax，MTV and EGFR mutations.Receiver operating characteristic(ROC) curve was used to identify the cutoffs of SUVmax，MTV.Multivariate Logistic regression analysis was used to analyze predictors of EGFR mutations.Results： In 141 patients enrolled in the study，EGFR mutations were identified in 74 patients(52.5%).Patients with EGFR mutations had significantly lower MTV than those with wild-type EGFR(P=0.033).No statistically significant correlation with SUVmax was found between patients with mutant and wild-type EGFR(P>0.05).ROC curve showed that the optimal cut-off for SUVmax，MTV to predict EGFR mutations were 8.56，24.0 cm3 respectively，with AUC of 0.522，0.604 respectively.Univariate analysis showed that non-smokers(P=0.001)，females(P=0.003)，patients with adenocarcinoma(P=0.022)and MTV＜24.0 cm3(P=0.003) were more likely to be EGFR mutation.Multivariate analysis showed that smoking status and MTV remained a significant predictors for EGFR mutation(P<0.05).Conclusion： MTV is an independent predictor of EGFR mutations in NSCLC，and has certain reference value in predicting EGFR mutation.

References:

［1］Hanahan D，Weinberg RA.Hallmarks of cancer：The next generation［J］.Cell，2011，144：646-674.
［2］Kumarakulasinghe NB，Van NZ，Soo RA.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)［J］.Respirology，2015，20(3)：370.
［3］Hirsch FR，Varella-Garcia M，Bunn Jr PA，et al.Epidermal growth factor receptor in non-small cell lung carcinomas：Correlation between gene copy number and protein expression and impact on prognosis［J］.Clin Oncol，2003，21：3798-3807.
［4］Sequist LV，Bell DW，Lynch TJ，et al.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer［J］.Clin Oncol，2007，25：587-595.
［5］Isaka T，Yokose T，Ito H，et al.Correlations between the EGFR mutation status and clinicopathological features of clinical stage Ⅰ lung adenocarcinoma［J］.Medicine，2015，42：e1784.
［6］Shi YK，Wang L，Han BH，et al.First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE)：A phase 3，open-label，randomized study［J］.Annals of Oncology，2017，28（10）：2443-2450.
［7］Shi X，Meng X，Sun X，et al.PET/CT imaging guided dose painting in radiation therapy［J］.Cancer Lett，2014，355：169-175.
［8］Konings R，Van Gool MH，Bard MP，et al.Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up［J］.Ann Nuclear Med，2016，30(5)：362-368.
［9］Yoo SW，Kim J，Chong A，et al.Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage Ⅳ non-small cell lung cancer［J］.Nucl Med Mol Imaging，2012，46：286-293.
［10］Liao S，Penney BC，Zhang H，et al.Prognostic value of the quantitative metabolic volumetric measurement on18F-FDG PET/CT in stage Ⅳ nonsurgical small-cell lung cancer［J］.Acad Radiol，2012，19：69-77.
［11］Nygaard AD，Holdgaard PC，Spindler KL，et al.The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC［J］.Br J Cancer，2014，110：363-368.
［12］Na II，Byun BH，Kim KM，et al.18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer：A single-institution retrospective analysis［J］.Lung Cancer，2010，67：76-80.
［13］Huang CT，Yen RF，Cheng MF，et al.Correlation of F-18 fluoro-2-deoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma［J］.Med Oncol，2010，27：9-15.
［14］Takamochi K，Mogushi K，Kawaji H，et al.Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma［J］.PLoS One，2017，12(4)：e0175622.
［15］Gu J，Xu S，Huang L，et al.Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer［J］.J Thoracic Dis，2018，10(2)：723-731.
［16］Mak RH，Digumarthy SR，Muzikansky A，et al.Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer［J］.Oncologist，2011，16：319-326.
［17］Putora PM，Fruh M，Muller J.FDG-PET SUVmax values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma［J］.Respirology，2013，18：734-735.
［18］Lee SM，Bae SK，Jung SJ，et al.FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status：A retrospective analysis of 206 patients［J］.Clin Nucl Med，2015，40：950-958.
［19］Minamimoto R，Jamali M，Gevaert O，et al.Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative (18)F FDG-PET/CT metrics ［J］.Oncotarget，2017，32：52792-52801.
［20］Meng X，Sun X，Mu D，et al.Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small cell lung cancer［J］.Int J Radiat Oncol Biol Phys，2012，82：960-966.
［21］Chung HW，Lee KY，Kim HJ，et al.FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma［J］.Cancer Res Clin Oncol，2014，140：89-98.
［22］Winther-Larsen A，Fledelius J，Sorensen BS，et al.Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib［J］.Lung Cancer，2016，94：81-87.

Memo

Memo:
National Natural Science Foundation of China（No.81671771）;国家自然科学基金（编号：81671771）；海南省自然基金创新团队项目（编号：2018CXTD347）
Last Update: 2019-02-01